Hans Maag, Ph.D. is a co-founder of Orfan Biotech. He started his distinguished career as a medicinal chemist at Hoffmann-LaRoche Inc in NJ, in the field of antibiotics and prostacyclins.
After moving to Syntex in Palo Alto, CA, he did research on antiviral agents with a focus on anti-HIV agents which lead to the development of Valganciclovir (ValcyteTM).
After the acquisition of Syntex by Roche, Dr. Maag became VP, Chemistry, and he led many project teams, from early lead identification to preclinical (pre-IND) development. During his time at Roche Palo Alto he was also in charge of the global task force on lead generation and was responsible for the computational chemistry group.
Expertise: Drug transport mechanisms across intestinal membrane.